Suppr超能文献

Ki-67表达的40%截断点在识别局部晚期三阴性乳腺癌患者2年内远处转移的发生中是否起作用?

Does a 40% Cut-off Point for Ki-67 Expression Have a Role in Identifying the Development of Distant Metastasis Within 2 Years in Locally Advanced Triple Negative Breast Cancer Patients?

作者信息

Setiawan Kelvin, Suryawisesa Ida Bagus, Widiana I Ketut, Sudarsa I Wayan

机构信息

Department of General Surgery, Udayana University Faculty of Medicine, Prof. Dr. I.G.N.G. Ngoerah General Hospital, Bali, Indonesia.

Division of Oncology Surgery, Department of Surgery, Udayana University Faculty of Medicine, Prof. Dr. I.G.N.G. Ngoerah General Hospital, Bali, Indonesia.

出版信息

Eur J Breast Health. 2023 Oct 1;19(4):274-278. doi: 10.4274/ejbh.galenos.2023.2023-4-5. eCollection 2023 Oct.

Abstract

OBJECTIVE

Triple negative breast cancer (TNBC) has a higher proportion of patients with distant recurrence or metastasis. Ki-67 has been suggested as an essential factor in cancer grading and prognostic evaluation, although there is still a debate regarding the Ki-67 cut-off value in TNBC. The aim of this study was to determine the role of Ki-67 expression using a 40% cut-off point as a risk factor for developing distant metastasis within two years in patients with TNBC.

MATERIALS AND METHODS

This analytical observational study was conducted with a case-control design from January 2021-2022. Subjects were divided into two groups (metastasis within two years or more than two years after diagnosis). Bivariate analysis was conducted using chi-square test and odds ratio (OR) was also analyzed.

RESULTS

A total of 66 subjects were included. In patients with metastasized TNBC and a Ki-67 expression of ≥40%, 29 patients (55.8%) had metastasis occurring in ≤2 years and 23 patients (44.2%) had metastasis occurring in >2 years; in patients with metastasized TNBC and a Ki-67 expression of <40%, 4 patients (28.6%) had metastasis occurring in ≤2 years and 10 patients (71.4%) had metastasis occurring in >2 years. Chi-square analysis ( = 0.071) indicated no significant association between patients with Ki-67 expression of ≥40% and <40% with metastasis within 2 years [OR 3.152 (confidence interval: 95% 0.875-11.362)].

CONCLUSION

Ki-67 protein expression of over 40% in patients with locally-advanced TNBC does not indicate a greater risk of distant metastasis in the first two years after diagnosis.

摘要

目的

三阴性乳腺癌(TNBC)患者远处复发或转移的比例较高。Ki-67被认为是癌症分级和预后评估的一个重要因素,尽管关于TNBC中Ki-67的临界值仍存在争议。本研究的目的是确定以40%为临界值的Ki-67表达作为TNBC患者两年内发生远处转移的危险因素的作用。

材料与方法

本分析性观察研究采用病例对照设计,时间为2021年1月至2022年。将受试者分为两组(诊断后两年内转移或两年后转移)。采用卡方检验进行双变量分析,并分析比值比(OR)。

结果

共纳入66名受试者。在Ki-67表达≥40%的转移性TNBC患者中,29例(55.8%)在≤2年内发生转移,23例(44.2%)在>2年内发生转移;在Ki-67表达<40%的转移性TNBC患者中,4例(28.6%)在≤2年内发生转移,10例(71.4%)在>2年内发生转移。卡方分析(=0.071)表明,Ki-67表达≥40%和<40%的患者与两年内转移之间无显著关联[OR 3.152(置信区间:95% 0.875-11.362)]。

结论

局部晚期TNBC患者中Ki-67蛋白表达超过40%并不表明在诊断后的头两年内远处转移风险更高。

相似文献

2
Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer.
Clin Transl Oncol. 2018 Nov;20(11):1448-1454. doi: 10.1007/s12094-018-1877-5. Epub 2018 Apr 18.
4
Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis.
Front Oncol. 2019 Oct 17;9:1068. doi: 10.3389/fonc.2019.01068. eCollection 2019.
5
Risk factors for distant metastasis of patients with primary triple-negative breast cancer.
Biosci Rep. 2019 Jun 4;39(6). doi: 10.1042/BSR20190288. Print 2019 Jun 28.
7
Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Ann Diagn Pathol. 2015 Feb;19(1):37-42. doi: 10.1016/j.anndiagpath.2014.10.003. Epub 2014 Oct 25.
9
Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis.
Onco Targets Ther. 2014 Sep 26;7:1733-42. doi: 10.2147/OTT.S66692. eCollection 2014.
10
Breast-Conserving Surgery in Triple-Negative Breast Cancer: A Retrospective Cohort Study.
Evid Based Complement Alternat Med. 2023 Jan 17;2023:5431563. doi: 10.1155/2023/5431563. eCollection 2023.

引用本文的文献

本文引用的文献

1
Prognostic factors in triple-negative breast cancer: a retrospective cohort.
Rev Assoc Med Bras (1992). 2021 Jul;67(7):950-957. doi: 10.1590/1806-9282.20210249.
2
Triple-negative breast cancer: promising prognostic biomarkers currently in development.
Expert Rev Anticancer Ther. 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984.
3
Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis.
Front Oncol. 2019 Oct 17;9:1068. doi: 10.3389/fonc.2019.01068. eCollection 2019.
4
Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer.
Breast. 2020 Feb;49:33-40. doi: 10.1016/j.breast.2019.10.006. Epub 2019 Oct 23.
5
Association between MRI Features and Standardized Uptake Value of 18F-FDG PET/CT in Triple-Negative Breast Cancer.
Oncol Res Treat. 2018;41(11):706-711. doi: 10.1159/000492341. Epub 2018 Oct 16.
6
Survival Study of Triple-Negative and Non-Triple-Negative Breast Cancer in a Brazilian Cohort.
Clin Med Insights Oncol. 2018 Jul 27;12:1179554918790563. doi: 10.1177/1179554918790563. eCollection 2018.
7
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
Eur J Cancer. 2017 Apr;75:284-298. doi: 10.1016/j.ejca.2017.01.017. Epub 2017 Feb 28.
9
Prognostic and predictive value of Ki-67 in triple-negative breast cancer.
Oncotarget. 2016 May 24;7(21):31079-87. doi: 10.18632/oncotarget.9075.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验